Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43150| Title: | Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study | Authors: | Joris, S Denys, H Collignon, J Rasschaert, M de Roodenbeke, DT Duhoux, FP Canon, JL Tejpar, S MEBIS, Jeroen Decoster, L Aftimos, P De Grève, J |
Issue Date: | 2023 | Publisher: | ELSEVIER | Source: | ESMO Open, 8 (6) (Art N° 102041) | Abstract: | The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR). | Keywords: | agnostic NGS;olaparib;colorectal cancer;parathyroid cancer;biliary tract cancer;BRCA1;BRCA2;CHEK2;ATM | Document URI: | http://hdl.handle.net/1942/43150 | e-ISSN: | 2059-7029 | DOI: | 10.1016/j.esmoop.2023.102041 | ISI #: | 001113986700001 | Rights: | 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1.pdf | Published version | 375.25 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.